|

The Effect of Semaglutide on Cardiovascular Markers and Liver Function

RECRUITINGSponsored by Attikon Hospital
Actively Recruiting
SponsorAttikon Hospital
Started2022-03-01
Est. completion2023-03-01
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06301191

Summary

Fifty patients with diabetes mellitus type 2 and non-alcoholic fatty liver disease (NAFLD) will be enrolled in the study. 25 patients will treated with semaglutide and 25 patients with dipeptidyl peptidase 4 (D-PP4) inhibitors. At baseline, at four and at 12 months will evaluate the endothelial, cardiovascular and liver function.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Diabetes Mellitus type 2
* NAFLD

Exclusion Criteria:

* malignancies
* chronic inflammatory disease
* chronic kidney disease (estimated glomerular filtration rate \<60 ml/min/m2 for a period of at least 90 days)
* peripheral vascular disease
* retinopathy
* previous therapy with a Glucagon-like peptide-1 agonist.
* None of the female patients was on hormone replacement treatment.

Conditions3

DiabetesDiabetes Type 2Liver Disease

Browse More Trials

Diabetes trialsLiver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.